Barinthus Biotherapeutics to merge with Clywedog Therapeutics.

Barinthus Biotherapeutics, a clinical-stage biopharmaceutical company, agreed to merge with Clywedog Therapeutics, a private company advancing novel breakthrough medicines in diabetes. Financial terms were not disclosed. “We believe that the combination of Barinthus Bio and Clywedog will create immediate value and long-term upside for all stakeholders by diversifying our pipeline and increasing the number of meaningful clinical milestones. The combined team will bring a deep scientific understanding of metabolic and autoimmune spaces together with strong clinical development experience, positioning us well to execute for patients and shareholders. I am honored to have the opportunity to lead an exceptional team and am truly excited to advance our highly differentiated pipeline of disease modifying therapies for Type 1 and Type 2 diabetes, and celiac disease,” Bill Enright, Barinthus Bio CEO.